Karolina P. S.
- Country
- Poland
- Department
- NA
Research Overview
- Investigation of RO7121932 Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics in Multiple Sclerosis Patients
- Comparative Efficacy and Safety Study of CYB704 and Ocrelizumab in Relapsing Multiple Sclerosis Patients
- Efficacy and Safety of Remibrutinib in Patients with Secondary Progressive Multiple Sclerosis: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study
Data & Insights
Has run more than one trial at 155 of 378 partner sites.
Specializations
Neurological Disorders
The investigator specializes in the study of Multiple Sclerosis (MS), focusing on innovative therapeutic approaches for this complex neurological condition.
- Autoimmune Neurological Disorders
- Central Nervous System Pathologies
- Neuroimmunology
Their research encompasses investigating novel treatment modalities and therapeutic agents for managing MS symptoms and disease progression.
Treatment Assessment
Expertise in evaluating safety and tolerability profiles of experimental treatments, with particular attention to immunological responses in MS patients.
- Drug Safety Evaluation
- Immunological Response Assessment
- Treatment Tolerability Studies
The investigator focuses on comprehensive assessment of therapeutic interventions through both intravenous and subcutaneous administration routes.
Clinical Pharmacology
Specialized focus on pharmacokinetics and pharmacodynamics in the context of Multiple Sclerosis treatments.
- Drug Metabolism Studies
- Therapeutic Response Monitoring
- Biomarker Analysis
Their work includes detailed analysis of drug behavior and therapeutic effects in the treatment of MS.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.